SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories declines on reporting 14% fall in Q3 consolidated net profit

13 Feb 2023 Evaluate

Alkem Laboratories is currently trading at Rs. 3257.05, down by 41.00 points or 1.24 % from its previous closing of Rs. 3298.05 on the BSE.

The scrip opened at Rs. 3300.00 and has touched a high and low of Rs. 3305.00 and Rs. 3194.15 respectively. So far 4147 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3720.00 on 30-Mar-2022 and a 52 week low of Rs. 2835.00 on 16-May-2022.

Last one week high and low of the scrip stood at Rs. 3346.35 and Rs. 3020.05 respectively. The current market cap of the company is Rs. 38701.99 crore.

The promoters holding in the company stood at 57.16%, while Institutions and Non-Institutions held 20.85% and 21.99% respectively.

Alkem Laboratories has reported fall of 11.03% in its net profit at Rs 388.89 crore for third quarter ended December 31, 2022 as compared to Rs 437.09 crore for the same quarter in the previous year. However, total income of the company increased by 5.05% at Rs 2,357.46 crore for the quarter under review as compared Rs 2,244.08 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported fall of 13.76% in its net profit at Rs 459.96 crore for third quarter ended December 31, 2022 as compared to Rs 533.35 crore for the same quarter in the previous year. However, total income of the company increased by 15.48% to Rs 3,086.24 crore for the quarter under review as compared to Rs 2,672.50 crore for the same quarter in the previous year.

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×